Antibody drug conjugates

Antibody drug conjugates (ADCs)

LUNGevity is partnering with PeerView Oncology, a medical education organization, to develop a learning session for providers on antibody drug conjugates, also known as ADCs. Antibody drug conjugates (ADCs) are a new class of targeted medicines that deliver chemotherapy agents to cancer cells. One ADC has so far been approved by the U.S. FDA for HER2-mutated lung cancer, and many more are being studied in clinical trials.

LUNGevity and PeerView are interested in your knowledge of ADCs and what, if anything, you are interested in knowing more about related to ADCs. The survey findings will be included in the medical education course for providers so that they, too, can be more knowledgeable about the patient survivor community's knowledge around ADCs.

The ADC medical education program will be held live at ASCO 2023 in Chicago the weekend of June 3-4. It will also be available after ASCO as an online medical education offering on PeerView's website. This activity is supported by independent educational grants from AstraZeneca, BioAtla, Inc., Daiichi Sankyo, Inc., Gilead Sciences, Inc., and Sanofi.

If you have questions, please contact Nikki Martin at nmartin@lungevity.org. Thank you so much for your survey feedback!

Question Title

* 1. How familiar are you with the ADCs?

Not at all familiar—I have never heard of them

Somewhat familiar—I have read or heard about them, but do not know very much

Quite familiar—I have done my research and am interested in learning more

I have personal experience—I have received treatment with the currently approved ADC trastuzumab deruxtecan (Enhertu)

I have personal experience—I have participated in a clinical trial of an ADC

Other (please specify)

Question Title

* 2. What would you like to know/learn about the new class of antibody drug conjugates (ADCs) being studied in lung cancer (select all that apply)?

What types of therapies are the ADCs (chemotherapies, targeted therapies, hybrid of the two, or something else)?

How do ADCs work?

Which patients with lung cancer could benefit from ADCs?

Which biomarker tests, if any, are needed to decide if an ADC might be a good option for a patient with lung cancer?

What are the benefits of the ADCs in lung cancer, and how do the benefits seen in studies compare with those from other available therapies?

What are the side effect profiles of the ADCs?

Other (please specify)

None of the above